A retrospective study suggested Vistide significantly improved the lives of 70% of severely ill ME/XCFS patients.
In a first for ME/CFS, at the HHV6 Conference in Paris Dr. Peterson reported a retrospective study indicated a little used anti-herpesvirus drug called Vistide significantly helped 70% of severely ill patients – with many able to return to work. With this unusually high success rate in this difficult to treat group Peterson called for multi-center studies to build on these results.
Click here to read the blog on the Simmaron Foundation website
Don't Miss Another Blog!
Like this blog?
Make sure you don’t miss another one by registering for our free ME/CFS and Fibromyalgia blogs here..
Wow – thanks Cort – your own researches are what you might say on a roll now.
I really hope a clinical trial and paper is followed up with this.This is something that can prove to the FDA, for a subset of patients with Severe ME, that this drug could make a difference. I know the only down fall is it’s infused over a long time but what about Valcyte it’s sister drug? This can open the door to hard hitting anti-virals .